Search
Streptococcus pneumoniae type 7F capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB10297ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … * serotype 7F individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197).
Streptococcus pneumoniae type 19A capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB10298ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … * serotype 19A individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197).
Streptococcus pneumoniae type 12F capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB16716ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … * serotype 12F individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197).
Streptococcus pneumoniae type 16F capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB19345ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … _ serotype 16F individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of _Corynebacterium diphtheriae_ strain C7 (β197).
Streptococcus pneumoniae type 23B capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB19349ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … _ serotype 23B individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of _Corynebacterium diphtheriae_ strain C7 (β197).
Streptococcus pneumoniae type 24F capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB19350ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … _ serotype 24F individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of _Corynebacterium diphtheriae_ strain C7 (β197).
Streptococcus pneumoniae type 31 capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB19351ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … _ serotype 31 individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of _Corynebacterium diphtheriae_ strain C7 (β197).
Streptococcus pneumoniae type 35B capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB19352ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … _ serotype 35B individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of _Corynebacterium diphtheriae_ strain C7 (β197).
Alcestobart
go.drugbank.com/drugs/DB28487InvestigationalAlcestobart is under investigation in clinical trial NCT05909904 (A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma). … Alcestobart is a biologic drug.
Refanezumab
go.drugbank.com/drugs/DB14908InvestigationalRefanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients).